

WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[HA466 trade name]*

Efavirenz/lamivudine /tenofovir disoproxil fumarate 600mg/300mg/300mg tablet

[HA466 trade name], manufactured at Mylan Laboratories Limited, Sinnar, Nashik, Maharashtra state, India, was included in the WHO list of prequalified medicinal products for the treatment of HIV/AIDS on 25 October 2010.

[HA466 trade name] is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients weighing at least 35 kg. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredients of [HA466 trade name] are efavirenz, lamivudine, tenofovir disoproxil fumarate.

The efficacy and safety of efavirenz, lamivudine, tenofovir disoproxil fumarate are well established based on extensive clinical experience in the treatment of HIV/AIDS.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of efavirenz, lamivudine and tenofovir disoproxil fumarate in HIV/AIDS, the team of assessors advised that [HA466 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [HA466 trade name] in the list of prequalified medicinal products.

Summary of prequalification status for [HA466 trade name]:

Initial acceptance	Date	Outcome
Status on PQ list	25 October 2010	Listed
Quality	14 October 2010	MR
Bioequivalence	15 October 2010	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
API	28 May 2009	MR
FPP	11 August 2009	MR
GCP/GLP (re-)inspection	21 May 2010	MR
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard]	GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification	

The table represents the status of relevant completed activities only.

Requalification	30 July 2019
------------------------	--------------

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.